Clinical effects of abrupt withdrawal from tri-cyclic antidepressants and monoamine oxidase inhibitors after long-term treatment.
51 psychiatric outpatients with depressive, anxiety and phobic neuroses were withdrawn from their maintenance treatment with tricyclic antidepressant drugs or the monoamine oxidase inhibitor, phenelzine, at a time mutually agreed between patient and doctor. Self-ratings of anxiety and depression were recorded at the time of withdrawal and at weekly intervals thereafter for 4 weeks. An increase in symptoms after withdrawal was found to be more likely after longer duration of maintenance treatment and in patients taking phenelzine.
D000328:Adult; D000929:Antidepressive Agents, Tricyclic / Q000627:therapeutic use*; D001008:Anxiety Disorders / Q000188:drug therapy*; D003866:Depressive Disorder / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010624:Phenelzine / Q000627:therapeutic use*; D010698:Phobic Disorders / Q000188:drug therapy*; D012008:Recurrence; D013375:Substance Withdrawal Syndrome / Q000175:diagnosis; D013997:Time Factors
D000929:Antidepressive Agents, Tricyclic; D010624:Phenelzine